• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Computer Concepts for Medical Device Design

    IVD Manufacturers Are Being Put to the Test

    The New State of Medtech Outsourcing

    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—June 3

    CardioRenal’s TENOR Device Receives Breakthrough Device Designation from FDA

    LifeQ Unveils New 24-Hour Sleep Solution

    Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll

    EvoEndo Names CEO and Chief Operating Officer
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Computer Concepts for Medical Device Design

    IVD Manufacturers Are Being Put to the Test

    The New State of Medtech Outsourcing

    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Checking Up on Surgical Robotics

    Building a Network: How Synchron Is Developing a New Device—and a New Market

    Six Lessons Learned on Developing a Strong Company Culture

    As Hiring Slows, Companies Look Inward to Fulfill Talent Needs

    Artificial Intelligence: Medtech Opportunity or Health Danger?
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    Cirtec Medical

    Medbio LLC

    LEMO USA Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    6 Considerations for Companies on the Cusp of Being Acquired

    3 Key Elements to Consider When Managing a Medtech Sales Force

    Tech-Enabled Virtual Speech Therapy Improves Speech & Communication Skills

    Practical Strategies for Digitization and Integration in Medtech Manufacturing

    Sensors: The Heart of Minimally Invasive Equipment Technology
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    Cirtec Medical

    Medbio LLC

    LEMO USA Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure

    Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy.

     Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
    Business Wire05.31.17
    W.L. Gore & Associates Inc. has announced positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ischemic stroke and new brain infarct. The data were shared May 16 at the European Stroke Organisation Conference (ESOC) in Prague, Czech Republic. Gore plans to submit the positive data to the U.S. Food and Drug Administration (FDA) to seek a PFO indication for the GORE®CARDIOFORM Septal Occluder by year's end.
     
    “The REDUCE data is groundbreaking for patients who have suffered a cryptogenic stroke attributed to a PFO,” said Scott Kasner, M.D., a neurologist in the Perelman School of Medicine at the University of Pennsylvania, and U.S. Neurology National Principal Investigator for the REDUCE Study. “Until now, there has never been a study of a PFO closure device that showed statistically significant reduction in stroke recurrence in the primary intent-to-treat analysis. Other PFO closure device trials had to rely on secondary analysis, including following patients for up to a decade, before achieving statistical significance. Also of note is the level of safety the GORE CARDIOFORM Septal Occluder demonstrated, with no significant difference shown in the rate of serious adverse events between patients implanted with the device and those in the control arm. This trial demonstrates noteworthy verification that PFO closure with the GORE CARDIOFORM Septal Occluder is a valuable procedure to reduce recurrent stroke and brain infarct when utilized in an appropriate patient population.”
     
    The controlled, open-label REDUCE study assessed the efficacy and safety of PFO closure using Gore Septal Occluder Devices in 664 randomized subjects, ages 18 to 59 with a history of cryptogenic stroke, across 63 investigational sites in seven countries. The trial met its primary endpoint by showing a statistically significant, 76.6 percent (p = 0.001), reduction in recurrent ischemic stroke in patients that underwent PFO closure in conjunction with antiplatelet therapy versus those who underwent antiplatelet therapy alone after an average of 3.4 years follow-up.
     
    In addition to the primary endpoint of reduction of recurrent stroke, the study also met its co-primary endpoint of reduction of new brain infarct, inclusive of silent brain infarct (SBI), through PFO closure. An increased risk of clinical stroke, dementia, and cognitive dysfunction has been associated with SBI. This marks the first time a study assessed the relationship between PFO closure and reduction of new brain infarct. Patients underwent baseline and two-year follow-up MRI scans to determine if new brain infarct occurred. New brain infarct was present in 5.7 percent of test arm subjects and 11.3 percent of control arm subjects, yielding a 49.6 percent (p = 0.024) relative risk reduction for PFO closure on new brain infarct.
     
    The data showed no difference in the subject-based rate of serious adverse events between test and control groups. Device- and procedure-related serious adverse events occurred in 1.4 and 2.5 percent, respectively, of test patients. Patients experienced low rates of bleeding, deep vein thrombosis, and pulmonary embolism, with no significant difference between test and control groups. There was a significantly higher rate of serious atrial fibrillation in the test group (2.3 percent versus 0.4 percent) but the majority of atrial fibrillation was peri-procedural (80 percent had onset within 30 days of the closure procedure) and had rapid resolution (70 percent with resolution within two days of onset).
     
    In the United States, stroke is the leading cause of long-term severe disability and the fourth leading cause of death. Roughly 25 percent of first-time strokes are cryptogenic, or due to unknown cause. Studies have shown that PFO can be found in up to 40 to 50 percent of patients who have had a cryptogenic stroke.
     
    Most people with a PFO—a hole occurring in the upper wall between the left and right atria of the heart — do not experience any issues when blood flows from one atrium to the other; however, serious problems such as stroke can arise if a blood clot passes from the right to left atria through a PFO and then to the brain. The data from the REDUCE Study suggest the risk of recurrent stroke can be dramatically reduced when the PFO is closed using Gore Septal Occluder Devices.
     
    “It is of the utmost importance to us to be transparent and share clinical data as quickly as possible,” said Jake Goble, Ph.D., Gore Structural Heart Pipeline leader. “We completed our two-year primary endpoint follow-up with patients in March and have worked diligently to release these important data to the public. Closure of PFO to reduce recurrent strokes and brain infarcts is not widely practiced today, mainly due to a lack of sufficient data. We’re excited by the very positive results from our REDUCE study. We are looking forward to our next steps of taking the GORE CARDIOFORM Septal Occluder through the submission process to make this viable treatment option for recurrent cryptogenic stroke available to physicians and their patients.”
     
    The GORE CARDIOFORM Septal Occluder is inserted through a catheter that is placed in a leg vein and advanced to the heart. In the United States, the GORE CARDIOFORM Septal Occluder is currently approved for closure of atrial septal defects (ASDs), and is under investigation for the closure of PFOs. It is designed with two independent conformable discs that span and cover the anatomy. The minimal wire frame of the device provides optimal apposition to the anatomy and is covered in Gore’s proprietary, thromboresistant ePTFE material, allowing tissue ingrowth for short-and long-term performance.
     
    Gore's Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers.
     
    W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments—from revolutionizing the outerwear industry with GORE-TEX fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. Headquartered in Newark, Del., Gore employs approximately 10,000 associates and generates annual revenues that exceed $3 billion.
    Related Searches
    • Materials
    • catheter
    • medical
    • 2.3 percent
    Related Knowledge Center
    • Cardiovascular
    Suggested For You
    Study Confirms Extended Continuous Cardiac Monitoring is More Efficient Than Holter Monitoring Study Confirms Extended Continuous Cardiac Monitoring is More Efficient Than Holter Monitoring
    Positive Results from Boston Scientific Positive Results from Boston Scientific's Bronchial Thermoplasty Study
    Is Your Biocompatibility Program on the Edge? Is Your Biocompatibility Program on the Edge?
    New 510(k) Approach Would Leverage FDA Objective Criteria New 510(k) Approach Would Leverage FDA Objective Criteria
    FDA Clears CrossBay Medical FDA Clears CrossBay Medical's IVF Embryo Transfer Catheter Set
    FDA Approval for Medtronic’s MR-Conditional Quadripolar CRT-Pacemakers FDA Approval for Medtronic’s MR-Conditional Quadripolar CRT-Pacemakers
    Industry Offers Support for Gottlieb Confirmation Industry Offers Support for Gottlieb Confirmation
    FDA Approves First First Flexible Shaver for Interventional Gastroenterology FDA Approves First First Flexible Shaver for Interventional Gastroenterology
    FDA Clears Samsung FDA Clears Samsung's Digital Radiography System
    FDA Designates Medtronic Action as Class I Recall FDA Designates Medtronic Action as Class I Recall
    FDA Clears First Portable Unified Respiratory System for Patients on a Ventilator FDA Clears First Portable Unified Respiratory System for Patients on a Ventilator
    Study Shows Medtronic Left Ventricular Assist Devices Have Positive Results at One Year Study Shows Medtronic Left Ventricular Assist Devices Have Positive Results at One Year
    FDA Clears ETS Wound Care FDA Clears ETS Wound Care's Advanced Wound Matrix
     Gore Unveils Next Evolution for TIPS Procedures: Lasting Diameter Control Gore Unveils Next Evolution for TIPS Procedures: Lasting Diameter Control
    GORE TIGRIS Vascular Stent Gains Health Canada Approval for Treatment of PAD GORE TIGRIS Vascular Stent Gains Health Canada Approval for Treatment of PAD

    Related Breaking News

    • Cardiovascular
      Study Confirms Extended Continuous Cardiac Monitoring is More Efficient Than Holter Monitoring

      Study Confirms Extended Continuous Cardiac Monitoring is More Efficient Than Holter Monitoring

      Data shows Zio by iRhythm Cardiac Monitoring shortens time to diagnosis after cryptogenic stroke.
      Globe Newswire 06.02.17

    • Surgical
      Positive Results from Boston Scientific

      Positive Results from Boston Scientific's Bronchial Thermoplasty Study

      Results from evaluation of real-world patients presented at American Thoracic Society International Conference.
      PR Newswire 05.25.17

    • Testing
      Is Your Biocompatibility Program on the Edge?

      Is Your Biocompatibility Program on the Edge?

      Regulatory changes in both Europe and the U.S. have created uncertainty among device makers.
      Thor Rollins, B.S., RN (NRCM), Senior Scientist, Nelson Laboratories 05.18.17


    • New 510(k) Approach Would Leverage FDA Objective Criteria

      New 510(k) Approach Would Leverage FDA Objective Criteria

      AdvaMed president issues statement in support of new legislation.
      Advanced Medical Technology Association 05.18.17

    • FDA Clears CrossBay Medical

      FDA Clears CrossBay Medical's IVF Embryo Transfer Catheter Set

      The device has also received clearance to commercialize the product in Europe by obtaining its CE mark.
      PR Newswire 05.18.17

    Loading, Please Wait..

    Trending
    • Healthcare Changes Prompt Medtronic To Merge Sales Force Medtronic, Inc. Is Combining Its U.S. Ca
    • Philips Names New Supervisory Board Chairman
    • A New Approach To Post-Market Surveillance
    • FDA Clears Sanara MedTech's Advanced Surgical Solution
    • Titan Medical Licenses Most IP To Intuitive; CEO Steps Down
    Breaking News
    • MPO's Most-Read Stories This Week—June 3
    • CardioRenal’s TENOR Device Receives Breakthrough Device Designation from FDA
    • LifeQ Unveils New 24-Hour Sleep Solution
    • Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll
    • EvoEndo Names CEO and Chief Operating Officer
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • Computer Concepts for Medical Device Design
    • IVD Manufacturers Are Being Put to the Test
    • The New State of Medtech Outsourcing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Stefan Pasiakos, PhD, Selected to Lead NIH Office of Dietary Supplements
    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Coatings World

    Latest Breaking News From Coatings World

    Indorama Ventures and Carbios Reaffirm Partnership to Build PET Biorecycling Plant
    AkzoNobel Powder Coatings Enhances Digital Services with Launch of My Interpon Portal
    PPG Opens Color Creation Lab with Chery Automobile in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—June 3
    CardioRenal’s TENOR Device Receives Breakthrough Device Designation from FDA
    LifeQ Unveils New 24-Hour Sleep Solution
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan
    ASM Research Chemicals Launches Development Packs for API Manufacturing
    WuXi Increases Manufacturing Capacity in Germany
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    L'Oréal North Asia President Discusses China's Consumer Sector Recovery & Premium Beauty Trends
    Kiehl’s Celebrates Pride by Supporting The Trevor Project
    L’Oréal & UNESCO Announce 2023 Laureates of the For Women in Science International Awards
    Happi

    Latest Breaking News From Happi

    Color Street Celebrates Pride Month with Limited-Edition ‘Over the Rainbow’ Nail Strips
    Olay Rolls Out Sensitive Skin Line
    World Taste & Smell Association's June 6 Webinar Looks at Smell and Multisensory Design
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX Digital, hubergroup and HP Top This Week’s Stories
    Mactac Acquires Canadian Roll Label Distributor Label Supply
    WestRock Advances its Commitment to a Sustainable Future
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Schreiner's Pharma-Comb IL Label supports clinical trial cancer medication
    First Anytron ANY-JET III digital label press installed in Korea
    FPA announces Kasie Fairbarn as elected ELC co-chair
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Harper Hygienics Launches Hemp-Based Intimate Care Wipes
    What You’re Reading on Nonwovens-Industry.com
    Biodiapers Signs Agreement with Sicam
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 3
    Augmedics Debuts New Features, Indications for xvision Platform
    Artelon Closes $20M Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Francisco Melo, Smart Skis, onsemi Top This Week’s Stories
    DIC Acquires Photoresist Polymers Manufacturer PCAS Canada
    Arkema Collaborates with Habitat for Humanity Philadelphia

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login